{"id":"https://openalex.org/W3112347154","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0613","title":"613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)","display_name":"613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)","publication_year":2020,"publication_date":"2020-11-01","ids":{"openalex":"https://openalex.org/W3112347154","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0613","mag":"3112347154"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0613","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0613","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0613","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-paper","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0613","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033675619","display_name":"Fiore Cattaruzza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fiore Cattaruzza","raw_affiliation_strings":["Amunix, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111147020","display_name":"Ayesha Nazeer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayesha Nazeer","raw_affiliation_strings":["Amunix, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051527877","display_name":"Zachary Lange","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zachary Lange","raw_affiliation_strings":["Amunix, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059098189","display_name":"Caitlin Koski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Caitlin Koski","raw_affiliation_strings":["Amunix, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071941321","display_name":"Mikhail Hammond","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mikhail Hammond","raw_affiliation_strings":["Amunix, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054997551","display_name":"Trang Dao-Pick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Trang Dao-Pick","raw_affiliation_strings":["Amunix, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026185277","display_name":"Angela Henkensiefken","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angela Henkensiefken","raw_affiliation_strings":["Amunix, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049851359","display_name":"Mika Kakefuda Derynck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mika Derynck","raw_affiliation_strings":["Amunix, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018783910","display_name":"Volker Schellenberger","orcid":"https://orcid.org/0000-0002-3491-8229","observed_orcids":["https://orcid.org/0000-0002-3491-8229"]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Volker Schellenberger","raw_affiliation_strings":["Amunix, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030418854","display_name":"Bryan A. Irving","orcid":"https://orcid.org/0000-0002-5093-013X","observed_orcids":["https://orcid.org/0000-0002-5093-013X"]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan Irving","raw_affiliation_strings":["Amunix, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210131535"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210131535"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":0.2736,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.58906606,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":null,"issue":null,"first_page":"A368.2","last_page":"A369"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.6050000190734863,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.6050000190734863,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.19529999792575836,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.05119999870657921,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/t-cell-engagers","display_name":"T-cell engagers","score":0.8349999785423279},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.5929999947547913},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.6919999718666077},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.5920000076293945},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.7319999933242798},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.878000020980835},{"id":"https://openalex.org/keywords/non-human-primate-safety","display_name":"non-human primate safety","score":0.7360000014305115},{"id":"https://openalex.org/keywords/therapeutic-index","display_name":"therapeutic index","score":0.7110000252723694},{"id":"https://openalex.org/keywords/t-cell-mediated-cytotoxicity","display_name":"T cell cytotoxicity","score":0.3400000035762787}],"concepts":[{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.8025091886520386},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5507156848907471},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.5054080486297607},{"id":"https://openalex.org/C2776714187","wikidata":"https://www.wikidata.org/wiki/Q212410","display_name":"Protease","level":3,"score":0.4363398551940918},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.382908433675766},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.31025177240371704},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.30501824617385864},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.15269562602043152},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12081331014633179}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2020-sitc2020.0613","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0613","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0613","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:251cfc5cf7644032b9a3fd31021d0f8c","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/251cfc5cf7644032b9a3fd31021d0f8c","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0613","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0613","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0613","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3180038610","https://openalex.org/W3133482751","https://openalex.org/W3088857581","https://openalex.org/W3094976805","https://openalex.org/W3082458287","https://openalex.org/W4200193838","https://openalex.org/W4362459740","https://openalex.org/W4298121561","https://openalex.org/W4282982885","https://openalex.org/W3088648667"],"abstract_inverted_index":{"Background":[0],"TCEs":[1],"are":[2,29,383,389],"effective":[3],"in":[4,10,54,111,170,175,181,187,229,299,332],"leukemias":[5],"but":[6,28,269,321],"have":[7],"been":[8,254],"challenging":[9],"solid":[11],"tumors":[12,55,231],"due":[13,31],"to":[14,19,32,59,81,142,154,205,220,235,258,279],"on-target,":[15],"off-tumor":[16],"toxicity.":[17],"Attempts":[18],"circumvent":[20],"CRS":[21,314,366],"include":[22],"step-up":[23],"dosing":[24,234],"and/or":[25,34],"complex":[26],"designs":[27],"unsuccessful":[30],"toxicity":[33,277],"enhanced":[35],"immunogenicity.":[36],"HER2-XPAT,":[37,126,159],"or":[38],"XTENylated":[39],"Protease-Activated":[40],"bispecific":[41],"T-Cell":[42],"Engager,":[43],"is":[44,359],"a":[45,116,127,346,360,368,384],"prodrug":[46,130,362],"TCE":[47,118,363],"that":[48],"exploits":[49],"the":[50,61,68,82,100,103,112,124,156,351,381],"protease":[51,245],"activity":[52,157],"present":[53],"vs.":[56,334],"healthy":[57],"tissue":[58,276],"expand":[60],"therapeutic":[62],"index":[63],"(TI).":[64],"The":[65],"core":[66],"of":[67,72,102,109,139,146,158,210,244,284],"HER2-XPAT":[69,202,224,252,261,285,328,358],"(PAT)":[70],"consists":[71],"2":[73,267],"tandem":[74],"scFvs":[75],"targeting":[76],"CD3":[77],"and":[78,93,163,178,193,197,214,275,286,315,345,367,395],"HER2.":[79],"Attached":[80],"core,":[83],"two":[84],"unstructured":[85],"polypeptide":[86],"masks":[87,105],"(XTEN)":[88],"sterically":[89],"reduce":[90],"target":[91],"engagement":[92],"extend":[94],"T1/2.":[95],"Protease":[96],"cleavage":[97,246,296],"sites":[98],"at":[99,266,306,318,324],"base":[101],"XTEN":[104],"enable":[106],"proteolytic":[107],"activation":[108,196],"XPATs":[110,382],"tumor":[113,128,212,227],"microenvironment,":[114],"unleashing":[115],"potent":[117,186,361],"with":[119,131,232,291,329,364],"short":[120],"T1/2,":[121],"further":[122],"improving":[123],"TI.":[125],"protease-activatable":[129],"wide":[132,369],"safety":[133,180,348],"margins,":[134],"can":[135],"co-opt":[136],"T-cells":[137],"regardless":[138],"antigenic":[140],"specificity":[141],"induce":[143],"T-cell":[144,189,195,248,264],"killing":[145,209],"HER2+":[147],"tumors.":[148],"Methods":[149],"Preclinical":[150],"studies":[151,388],"were":[152,288],"conducted":[153],"characterize":[155],"HER2-PAT":[160,184,308],"(cleaved":[161],"XPAT),":[162],"HER2-NonClv":[164,238,287],"(a":[165],"non-cleavable":[166],"XPAT)":[167],"for":[168,172,179,247,295,303,341,354],"cytotoxicity":[169,190,216,339],"vitro,":[171],"anti-tumor":[173],"efficacy":[174,396],"xenograft":[176],"models,":[177],"NHPs.":[182,373],"Results":[183],"demonstrated":[185,262],"vitro":[188],"(EC50":[191],"1-2pM)":[192],"target-dependent":[194],"cytokine":[198,273,316],"production":[199],"by":[200,309],"hPBMCs.":[201],"provided":[203],"up":[204,219,257,278],"14,000-fold":[206],"protection":[207,331],"against":[208,217],"HER2":[211,342],"cells":[213],"no":[215,240,365],"cardiomyocytes":[218],"1uM.":[221],"In":[222,250],"vivo,":[223],"induced":[225,312],"complete":[226],"regressions":[228],"BT-474":[230],"equimolar":[233],"HER2-PAT,":[236,335],"whereas":[237],"had":[239],"efficacy,":[241],"supporting":[242],"requirement":[243],"activity.":[249,356],"NHP,":[251],"has":[253],"dose-escalated":[255],"safely":[256],"42mg/kg":[259],"(MTD).":[260],"early":[263],"margination":[265],"mg/kg":[268],"largely":[270],"spared":[271],"CRS,":[272],"production,":[274],"42":[280],"mg/kg.":[281],"PK":[282],"profiles":[283],"comparable,":[289],"consistent":[290],"ex":[292],"vivo":[293],"stability":[294],"when":[297],"incubated":[298],"cancer":[300],"pts":[301],"plasma":[302],"7":[304],"days":[305],"37\u00b0C.":[307],"continuous":[310],"infusion":[311],"lethal":[313],"spikes":[317],"0.3":[319],"mg/kg/d":[320],"was":[322],"tolerated":[323],"0.25":[325],"mg/kg/d,":[326],"providing":[327],">1300-fold":[330],"tolerability":[333],">4":[336],"logs":[337],"over":[338,350],"EC50s":[340],"cell":[343],"lines,":[344],"20-fold":[347],"margin":[349],"dose":[352],"required":[353],"pharmacodynamic":[355],"Conclusions":[357],"TI":[370],"based":[371],"on":[372],"With":[374],"XTEN\u2019s":[375],"clinical":[376],"data":[377,397],"demonstrating":[378],"low":[379],"immunogenicity,":[380],"promising":[385],"solution.":[386],"IND":[387],"ongoing.":[390],"Additional":[391],"PK/PD,":[392],"cytokines,":[393],"safety,":[394],"will":[398],"be":[399],"presented.":[400]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2020-12-21T00:00:00"}